International Journal of Medicine and Data

Objective To observe and analyze the clinical effect and application value of calcium sensitizer levosimendan in the treatment of patients with decompensated heart failure. Methods A retrospective study was conducted to select 120 patients with decompensated heart failure (sample number: 120; Sample inclusion time: January 2023 - January 2024) was divided into control and experimental groups based on random ball touching, and the number of observed cases was highly consistent. Conventional treatment and calcium sensitizer levosimendan were respectively administered. The therapeutic effect was collected and analyzed. Results Compared with the control group (conventional treatment), the serological index (BNP, cTnI) of the experimental group (levosimendan treatment) after treatment was lower, the quality of life score (role function/emotional function/cognitive function/social function/physical function) was higher, and the cardiac function index (higher LVEF, lower LVEDD) of the experimental group after treatment was better than that of the control group. The differences were statistically significant (P<0.05). Conclusion Levosimendan treatment can effectively improve the serological level, promote the recovery of cardiac function and improve the quality of life in patients with decompensated heart failure, and has high application value.

Calcium ion sensitizer; Decompensated heart failure; Levosimendan; Therapeutic effect